1. Home
  2. GKOS vs HHH Comparison

GKOS vs HHH Comparison

Compare GKOS & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • HHH
  • Stock Information
  • Founded
  • GKOS 1998
  • HHH 2010
  • Country
  • GKOS United States
  • HHH United States
  • Employees
  • GKOS N/A
  • HHH N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • HHH Real Estate Investment Trusts
  • Sector
  • GKOS Health Care
  • HHH Real Estate
  • Exchange
  • GKOS Nasdaq
  • HHH Nasdaq
  • Market Cap
  • GKOS 5.4B
  • HHH 4.7B
  • IPO Year
  • GKOS 2015
  • HHH N/A
  • Fundamental
  • Price
  • GKOS $91.09
  • HHH $89.31
  • Analyst Decision
  • GKOS Strong Buy
  • HHH Buy
  • Analyst Count
  • GKOS 13
  • HHH 2
  • Target Price
  • GKOS $122.08
  • HHH $90.00
  • AVG Volume (30 Days)
  • GKOS 1.6M
  • HHH 298.1K
  • Earning Date
  • GKOS 10-29-2025
  • HHH 11-10-2025
  • Dividend Yield
  • GKOS N/A
  • HHH N/A
  • EPS Growth
  • GKOS N/A
  • HHH 234.68
  • EPS
  • GKOS N/A
  • HHH 5.10
  • Revenue
  • GKOS $469,820,000.00
  • HHH $1,834,033,000.00
  • Revenue This Year
  • GKOS $30.89
  • HHH N/A
  • Revenue Next Year
  • GKOS $24.36
  • HHH $21.07
  • P/E Ratio
  • GKOS N/A
  • HHH $17.48
  • Revenue Growth
  • GKOS 30.38
  • HHH 69.81
  • 52 Week Low
  • GKOS $73.16
  • HHH $61.41
  • 52 Week High
  • GKOS $163.71
  • HHH $90.27
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 60.41
  • HHH 74.38
  • Support Level
  • GKOS $80.91
  • HHH $78.00
  • Resistance Level
  • GKOS $102.80
  • HHH $90.27
  • Average True Range (ATR)
  • GKOS 4.63
  • HHH 1.90
  • MACD
  • GKOS 1.07
  • HHH 0.88
  • Stochastic Oscillator
  • GKOS 56.85
  • HHH 93.39

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.

Share on Social Networks: